## Kremer Ae, Kremer A

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6828305/publications.pdf

Version: 2024-02-01

98 papers 4,853 citations

34 h-index 102304 66 g-index

102 all docs  $\begin{array}{c} 102 \\ \\ \text{docs citations} \end{array}$ 

102 times ranked 7060 citing authors

#	Article	IF	CITATIONS
1	Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine, 2020, 58, 102925.	2.7	369
2	Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus. Gastroenterology, 2010, 139, 1008-1018.e1.	0.6	345
3	The biliary HCO3â <sup>-</sup> umbrella: A unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology, 2010, 52, 1489-1496.	3.6	286
4	Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology, 2012, 56, 1391-1400.	3.6	228
5	Uremic pruritus. Kidney International, 2015, 87, 685-691.	2.6	188
6	Pruritus in cholestasis: Facts and fiction. Hepatology, 2014, 60, 399-407.	3.6	179
7	SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Annals of the Rheumatic Diseases, 2021, 80, 1312-1316.	0.5	154
8	Fibroblast growth factor 21 is induced by endoplasmic reticulum stress. Biochimie, 2013, 95, 692-699.	1.3	141
9	The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis. Journal of Clinical Investigation, 2016, 126, 4346-4360.	3.9	130
10	Clinical Relevance of Circulating Nucleosomes in Cancer. Annals of the New York Academy of Sciences, 2008, 1137, 180-189.	1.8	129
11	Seladelpar (MBX-8025), a selective PPAR-δagonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. The Lancet Gastroenterology and Hepatology, 2017, 2, 716-726.	3.7	126
12	PU.1 controls fibroblast polarization and tissue fibrosis. Nature, 2019, 566, 344-349.	13.7	121
13	Increased frequencies of ILâ€31â€producing T cells are found in chronic atopic dermatitis skin. Experimental Dermatology, 2012, 21, 431-436.	1.4	107
14	Pathogenesis and Treatment of Pruritus in Cholestasis. Drugs, 2008, 68, 2163-2182.	4.9	98
15	Pathophysiology and current management of pruritus in liver disease. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 89-97.	0.7	90
16	Advances in hepatitis C therapy: What is the current state - what come's next?. World Journal of Hepatology, 2016, 8, 139.	0.8	85
17	Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology, 2016, 63, 1287-1298.	3.6	85
18	Receptors, cells and circuits involved in pruritus of systemic disorders. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 869-892.	1.8	82

#	Article	IF	CITATIONS
19	Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nature Communications, 2020, 11, 3774.	5.8	78
20	PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury. Gut, 2017, 66, 716-723.	6.1	77
21	Mas-related G protein–coupled receptor X2 and its activators in dermatologic allergies. Journal of Allergy and Clinical Immunology, 2021, 147, 456-469.	1.5	70
22	Pathogenesis and Management of Pruritus in PBC and PSC. Digestive Diseases, 2015, 33, 164-175.	0.8	61
23	Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1170-1178.e6.	2.4	61
24	Advances in Pathogenesis and Management of Pruritus in Cholestasis. Digestive Diseases, 2014, 32, 637-645.	0.8	58
25	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 781-793.	3.7	58
26	Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy. Journal of Hepatology, 2015, 62, 897-904.	1.8	57
27	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 179-187.e6.	2.4	57
28	Epithelia-Sensory Neuron Cross Talk Underlies Cholestatic Itch Induced by Lysophosphatidylcholine. Gastroenterology, 2021, 161, 301-317.e16.	0.6	57
29	S2kâ€Leitlinie zur Diagnostik und Therapie des chronischen Pruritus – Update – Kurzversion. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-873.	0.4	56
30	Peripheral Sensitization and Loss of Descending Inhibition Is a Hallmark of Chronic Pruritus. Journal of Investigative Dermatology, 2020, 140, 203-211.e4.	0.3	54
31	A High-Calorie Diet Aggravates Mitochondrial Dysfunction and Triggers Severe Liver Damage in Wilson Disease Rats. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 571-596.	2.3	50
32	Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases. Scientific Reports, 2016, 6, 30847.	1.6	48
33	Rare Loss-of-Function Mutation in SERPINA3 in Generalized Pustular Psoriasis. Journal of Investigative Dermatology, 2020, 140, 1451-1455.e13.	0.3	48
34	Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections. Nature Communications, 2021, 12, 1112.	5 <b>.</b> 8	44
35	Chronic Pruritus in the Absence of Skin Disease: Pathophysiology, Diagnosis and Treatment. American Journal of Clinical Dermatology, 2016, 17, 337-348.	<b>3.</b> 3	38
36	Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19. Journal of Clinical Virology, 2021, 139, 104847.	1.6	37

#	Article	IF	Citations
37	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. Journal of Hepatology, 2022, 77, 353-364.	1.8	36
38	Treatment of Pruritus Secondary to Liver Disease. Current Gastroenterology Reports, 2019, 21, 48.	1.1	34
39	Human CD4+ T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential. Clinical and Experimental Immunology, 2021, 205, 363-378.	1.1	34
40	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. Journal of Hepatology, 2022, 77, 1545-1553.	1.8	33
41	Management of Chronic Hepatic Itch. Dermatologic Clinics, 2018, 36, 293-300.	1.0	31
42	Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver International, 2022, 42, 112-123.	1.9	31
43	Lysophosphatidic acid activates satellite glia cells and Schwann cells. Glia, 2019, 67, 999-1012.	2.5	29
44	Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 751-759.	1.3	29
45	A group of cationic amphiphilic drugs activates MRGPRX2 and induces scratching behavior in mice. Journal of Allergy and Clinical Immunology, 2021, 148, 506-522.e8.	1.5	29
46	Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer. Journal of Clinical Investigation, 2020, 130, 2509-2526.	3.9	29
47	The Molecular Mechanism of Cholestatic Pruritus. Digestive Diseases, 2011, 29, 66-71.	0.8	28
48	Serum Autotaxin Activity Correlates With Pruritus in Pediatric Cholestatic Disorders. Journal of Pediatric Gastroenterology and Nutrition, 2016, 62, 530-535.	0.9	27
49	ADSCs and adipocytes are the main producers in the autotaxin–lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro. BMC Cancer, 2018, 18, 1273.	1.1	26
50	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. Journal of Hepatology, 2021, 74, 801-810.	1.8	26
51	Characterization and treatment of persistent hepatocellular secretory failure. Liver International, 2015, 35, 1478-1488.	1.9	24
52	IgA2 Antibodies against SARS-CoV-2 Correlate with NET Formation and Fatal Outcome in Severely Diseased COVID-19 Patients. Cells, 2020, 9, 2676.	1.8	24
53	S2k Guidelines for the diagnosis and treatment of chronic pruritus – update – short version. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-872.	0.4	23
54	Glycochenodeoxycholate Promotes Liver Fibrosis in Mice with Hepatocellular Cholestasis. Cells, 2020, 9, 281.	1.8	23

#	Article	IF	CITATIONS
55	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	1.8	21
56	Total bile acids in the maternal and fetal compartment in relation to placental ABCG2 expression in preeclamptic pregnancies complicated by HELLP syndrome. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 131-136.	1.8	20
57	Involvement of Neuro-Immune Interactions in Pruritus With Special Focus on Receptor Expressions. Frontiers in Medicine, 2021, 8, 627985.	1.2	20
58	What are new treatment concepts in systemic itch?. Experimental Dermatology, 2019, 28, 1485-1492.	1.4	18
59	Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers. Expert Review of Molecular Diagnostics, 2009, 9, 139-156.	1.5	17
60	Mediators of pruritus during cholestasis. Current Opinion in Gastroenterology, 2011, 27, 289-293.	1.0	17
61	Cholestatic pruritus: a retrospective analysis on clinical characteristics and treatment response. JDDG - Journal of the German Society of Dermatology, 2013, 11, 158-168.	0.4	16
62	Complementary roles of murine NaV1.7, NaV1.8 and NaV1.9 in acute itch signalling. Scientific Reports, 2020, 10, 2326.	1.6	16
63	Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis. Annals of the Rheumatic Diseases, 2021, 80, e87-e87.	0.5	15
64	Impact on followâ€up strategies in patients with primary sclerosing cholangitis. Liver International, 2023, 43, 127-138.	1.9	15
65	Blood Cytokine, Chemokine and Gene Expression in Cholestasis Patients with Intractable Pruritus Treated with a Molecular Adsorbent Recirculating System: A Case Series. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 799-805.	1.8	14
66	Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease. Current Hepatology Reports, 2020, 19, 86-95.	0.4	14
67	Clinical management of pruritus. JDDG - Journal of the German Society of Dermatology, 2015, 13, 101-114.	0.4	12
68	Enteroendocrine cells are a potential source of serum autotaxin in men. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 696-704.	1.8	12
69	Impact of Global Fxr Deficiency on Experimental Acute Pancreatitis and Genetic Variation in the FXR Locus in Human Acute Pancreatitis. PLoS ONE, 2014, 9, e114393.	1.1	10
70	Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis. Gut, 2019, 68, 1902-1903.	6.1	10
71	Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus. Frontiers in Medicine, 2021, 8, 641163.	1.2	9
72	Influence of the autotaxin-lysophosphatidic acid axis on cellular function and cytokine expression in different breast cancer cell lines. Scientific Reports, 2022, 12, 5565.	1.6	9

#	Article	IF	CITATIONS
73	Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis. Scientific Reports, 2019, 9, 8450.	1.6	8
74	Circulating Adaptive Immune Cells Expressing the Gut Homing Marker $\hat{l}\pm4\hat{l}^27$ Integrin Are Decreased in COVID-19. Frontiers in Immunology, 2021, 12, 639329.	2.2	8
75	Lysophosphatidic acid activates nociceptors and causes pain or itch depending on the application mode in human skin. Pain, 2022, 163, 445-460.	2.0	8
76	Successful treatment of COVIDâ€19 infection with convalescent plasma in Bâ€cellâ€depleted patients may promote cellular immunity. European Journal of Immunology, 2021, 51, 2478-2484.	1.6	8
77	Natural Tâ€cell ligands that are created by genetic variants can be transferred between cells by extracellular vesicles. European Journal of Immunology, 2018, 48, 1621-1631.	1.6	7
78	Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study. Journal of Hepatology, 2020, 73, S464-S465.	1.8	7
79	Discovery and Differential Processing of HLA Class II-Restricted Minor Histocompatibility Antigen LB-PIP4K2A-1S and Its Allelic Variant by Asparagine Endopeptidase. Frontiers in Immunology, 2020, 11, 381.	2.2	7
80	Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis. Microorganisms, 2021, 9, 1752.	1.6	6
81	Non-dermatological Challenges of Chronic Itch. Acta Dermato-Venereologica, 2020, 100, 22-27.	0.6	6
82	Pearls & Oy-sters: SARS-CoV-2 Infection of the CNS in a Patient With Meningeosis Carcinomatosa. Neurology, 2021, 96, 496-499.	1.5	5
83	Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11. Neoplasia, 2021, 23, 502-514.	2.3	5
84	Intrahepatic Cholestasis of Pregnancy. Geburtshilfe Und Frauenheilkunde, 2021, 81, 940-947.	0.8	5
85	Modulation of the extrinsic cell death signaling pathway by viral Flip induces acute-death mediated liver failure. Cell Death and Disease, 2019, 10, 878.	2.7	4
86	Cholestatischer Pruritus: eine retrospektive Analyse klinischer Charakteristika und des Therapieansprechens. JDDG - Journal of the German Society of Dermatology, 2013, 11, 158-169.	0.4	3
87	Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients. PLoS ONE, 2018, 13, e0208225.	1.1	3
88	Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma. Cancers, 2021, 13, 1183.	1.7	3
89	Brushing of bile duct stenoses for the true dignity. Liver International, 2012, 32, 698-700.	1.9	2
90	Purple urine in a patient after recovery from a SARS-CoV-2 infection. International Journal of Infectious Diseases, 2021, 105, 472-473.	1.5	2

#	Article	IF	CITATIONS
91	Successful Multidisciplinary Treatment with Secondary Metastatic Liver Resection after Downsizing by Palliative Second-Line Treatment of Colorectal Cancer: A Curative Option. Case Reports in Oncology, 2016, 9, 379-386.	0.3	1
92	How Much Liver Tissue Is Required for Sufficient Histological Staging in Patients with Primary Biliary Cholangitis?. Digestion, 2021, 102, 428-436.	1.2	1
93	[65-OR]. Pregnancy Hypertension, 2015, 5, 34.	0.6	O
94	Reply. Hepatology, 2015, 61, 2115-2115.	3.6	0
95	Can genetic testing guide the therapy of cholestatic pruritus? A case of benign recurrent intrahepatic cholestasis type 2 with severe nasobiliary drainageâ€refractory itch. Hepatology Communications, 2018, 2, 152-154.	2.0	0
96	ATU-09 $\hat{a}$ $\in$ Obeticholic acid treatment is associated with improved collagen morphometry in patients with primary biliary cholangitis. , 2019, , .		0
97	Endocrine Diseases. , 2016, , 267-270.		0
98	Hepatobiliary Diseases., 2016,, 253-266.		0